🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We will organize an international conference "Preparing for the Next Pandemic: Evolution, Pathogenesis and Virology of Coronaviruses" on December 2-5 at Awaji Yumebutai, Japan🇯🇵. Premier gathering of top scientists who are active in the forefront of COVID research. Please repost!

Escape of #SARS-CoV-2 KP1.1, LB.1 and KP3.3 from recently approved monoclonal antibodies. #Pemivibart/VYD222 is less efficient, #Sipavibart/ AZD3152 no longer neutralizes KP1.1, LB.1, and KP3.3 in cell systems. Congrats to Planas Delphine and coll.! biorxiv.org/content/10.110…

I’ve updated SARSCoV2 antibody-escape calculator w new deep mutational scanning data of Yunlong Richard Cao Fanchong Jian My interpretation: antigenic evolution currently constrained by pleiotropic effects of mutations on RBD-ACE2 affinity, RBD up-down position & antibody neutralization

In this new paper The Lancet Infectious Diseases, we showed that the variant XEC exhibits extensive immune evasion, and its new NTD mutations, which may introduce new glycosylation, can cause potency reduction of anti-RBD antibodies, probably through allosteric effects thelancet.com/journals/lanin…

SARS-CoV-2 variants NB.1.8.1 and XFG are spreading fast. In this new paper, we explain their high growth advantage. 1. XFG is strong in immune evasion but shows lower ACE2 binding. 2. NB.1.8.1 is very well-balanced between immune evasion and ACE2 usage. thelancet.com/journals/lanin…